Speaker Profile
Biography
Sungwon Lim is a seasoned bioengineer and entrepreneur who brings two decades of expertise in academia and biotech. Focused on expediting cancer treatment, his extensive background in therapeutic development led to the creation of ImpriMed. The company provides oncologists with a swift precision diagnostic tool, enabling tailored identification of the most effective available drugs for individual patients. He has received accolades such as the Life Science Voice's Top Industry Leaders Award and the 40 Under 40 in Cancer Award. Dr. Sungwon Lim exemplifies the fusion of biotechnology innovation and compassionate patient care, revolutionizing cancer treatment in the present.
Talk
Connecting the Right Drug to the Right Patient
ImpriMed offers AI-driven decision support to match the right drug to the right patient. The company's live-cell testing platform pinpoints the most effective therapies for individual cancer cases. The technology can also be applied to help pharmaceutical companies identify responder populations for novel drug candidates, de-risking and optimizing the clinical trial process.
AI for Clinical Decision Support Systems Showcase:
ImpriMed
AI-driven functional precision medicine solution for personalizing cancer treatment
Session Abstract – PMWC 2026 Silicon Valley
"The PMWC 2026 AI for Clinical Decision Support Showcase will provide a 15-30 minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative




